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summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease involving skin, peripheral joints, entheses, and axial 
skeleton. The disease is frequently associated with extrarticular manifestations (EAMs) and comorbidities.
In order to create a protocol for PsA diagnosis and global assessment of patients with an algorithm based on 
anamnestic, clinical, laboratory and imaging procedures, we established a DElphi study on a national scale, 
named Italian DElphi in psoriatic Arthritis (IDEA). 
After a literature search, a Delphi poll, involving 52 rheumatologists, was performed. On the basis of the litera-
ture search, 202 potential items were identified. 
The steering committee planned at least two Delphi rounds. In the first Delphi round, the experts judged each of 
the 202 items using a score ranging from 1 to 9 based on its increasing clinical relevance. The questions posed 
to experts were How relevant is this procedure/observation/sign/symptom for assessment of a psoriatic arthritis 
patient? Proposals of additional items, not included in the questionnaire, were also encouraged. The results of 
the poll were discussed by the Steering Committee, which evaluated the necessity for removing selected proce-
dures or adding additional ones, according to criteria of clinical appropriateness and sustainability.
A total of 43 recommended diagnosis and assessment procedures, recognized as items, were derived by com-
bination of the Delphi survey and two National Expert Meetings, and grouped in different areas. Favourable 
opinion was reached in 100% of cases for several aspects covering the following areas: medical (familial and 
personal) history, physical evaluation, imaging tool, second level laboratory tests, disease activity measure-
ment and extrarticular manifestations. After performing PsA diagnosis, identification of specific disease activity 
scores and clinimetric approaches were suggested for assessing the different clinical subsets.
Further, results showed the need for investigation on the presence of several EAMs and risk factors.
In the context of any area, a rank was assigned for each item by Expert Committee members, in order to create 
the logical sequence of the algorithm. The final list of recommended diagnosis and assessment procedures, by 
the Delphi survey and the two National Expert Meetings, was also reported as an algorithm.
This study shows results obtained by the combination of a DElphi survey of a group of Italian rheumatologists 
and two National Expert Meetings, created with the aim of establishing a clinical procedure and algorithm for 
the diagnosis and the assessment of PsA patients. 
In order to find accurate and practical diagnostic and assessment items in clinical practice, we have focused our 
attention on evaluating the different PsA domains. Hence, we conceived the IDEA algorithm in order to address 
PsA diagnosis and assessment in the context of daily clinical practice. 
The IDEA algorithm might eventually lead to a multidimensional approach and could represent a useful and 
practical tool for addressing diagnosis and for assessing the disease appropriately.
However, the elaborated algorithm needs to be further investigated in daily practice, for evidencing and proving 
its eventual efficacy in detecting and staging PsA and its heterogeneous spectrum appropriately.
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n	 INTRODUCTION
Psoriatic arthritis (PsA) is a chronic in-flammatory disease involving skin, 
peripheral joints, entheses, and axial skel-
eton. The disease is frequently associated 
with extrarticular manifestations (EAMs) 
and comorbidities (1). Diagnosis relies 
mainly on clinical evaluation and the CAS-
PAR (ClASsification criteria for Psoriatic 
ARthritis) criteria are often used in epi-
demiological and research studies, having 
high specificity (98.7%) and sensitivity 
(91.4%) (2, 3).
Frequently, peripheral patterns overlap 
with axial involvement leading to different 
phenotypical combinations and frequency, 
in which dactylitis, enthesitis, low back 
pain, oligo and mono arthritis significantly 
characterize the disease (4-7). Cutaneous 
domain represents another aspect leading 
to wide phenotypical heterogeneity. Psori-
asis generally occurs before articular mani-
festations; it can be contemporaneous with, 
or later than arthritis. Furthermore, the case 
of patients with arthritis and familiar pso-
riasis provides a PsA subset classified as 
sine psoriasis (8). 
In addition, in recent years the increase of 
clinical studies have outlined how PsA can 
be associated with extrarticular manifesta-
tions, also alternatively recognized as com-
orbities (9-13). Among these, the most fre-
quent are represented by uveitis (9), colitis 
(10), metabolic syndrome (MS) (11) and 
involvement of the cardiovascular system 
(12). Psychological aspects, such as de-
pressive symptoms and anxiety, represent 
important correlates of health related qual-
ity of life (HRQoL) (13). 
Hence, the new concept of psoriatic disease 
has identified this heterogeneous condition, 
abandoning the view of PsA as a merely 
articular and cutaneous mild inflammatory 
state (14). 
However, once the patient has been diag-
nosed with PsA, the variable clinical spec-
trum can make the assessment of disease 
activity a challenge both for articular and 
cutaneous aspects and for systemic mani-
festations (15, 16).
In order to find accurate, reliable, and fea-
sible activity measures useful in longitu-
dinal cohorts, clinical trials, and clinical 
practice, the Group for Outcome Measures 
in Rheumatology (OMERACT), and for 
Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA), have fo-
cused their attention on refining and assess-
ing the different PsA domains (16).
In particular, to assist the rheumatologist 
in the management of PsA, OMERACT 
Group proposed a core set of six core 
domains, represented by peripheral joint 
and skin activity, pain, patient global as-
sessment (PGA), physical function, and 
HRQoL. In addition, spinal disease, dac-
tylitis, enthesitis, fatigue, nail disease, ra-
diography, and acute-phase indices were 
considered important domains (17).
GRAPPA group highlights that assessment 
of PsA patients requires full consideration 
of all major disease domains, including pe-
ripheral arthritis, axial disease, enthesitis, 
dactylitis, psoriasis, and nail disease. Fur-
ther, the impact of PsA on pain, function, 
QoL, and structural damage needs to be 
assessed (18). In addition, a comprehen-
sive assessment of other potential related 
conditions should be considered, including 
uveitis, inflammatory bowel disease (IBD), 
cardiovascular disease, obesity, MS, gout, 
diabetes mellitus (DM), liver disease, de-
pressive and anxiety-symptoms (18-22).
In recent years, in psoriasis (23) and PsA 
(24-29), several studies have applied Del-
phi procedures (30, 31) for different aims, 
mainly focused on better diagnosis and as-
sessment of these clinical conditions.
In particular, in 2015, in the context of pso-
riasis, Italian dermatologists performed a 
Delphi procedure involving 50 dedicated 
dermatological centres (23). This led to the 
definition of a multidimensional assess-
ment algorithm for psoriasis diagnosis and 
assessment which was potentially useful 
for proving sensitivity sustainable in daily 
clinical practice, named PSOCUBE. It in-
cludes a three-dimensional table compris-
ing 14 clinical examinations and history-
recording items, 32 laboratory screenings 
and instrumental exams and 11 clinimetric 
scores (23).
In order to create PsA diagnosis and global 
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assessment protocol and an algorithm based 
on anamnestic, clinical, laboratory and im-
aging procedures, we established a Delphi 
study on a national scale, named Italian 
DElphi in psoriatic Arthritis (IDEA).
n	 MATERIALS AND METHODS
As a first step, all the evaluations (patient 
anamnesis, clinical evaluation, laboratory 
tests, imaging procedures) considered use-
ful for the diagnosis, and the domains for 
the assessment, were identified by an ex-
pert board dictating the items, through a 
literature search. 
Subsequently, a Delphi poll involving 52 
rheumatologists, representative of the Ital-
ian rheumatologic community and with ex-
pertise in current good clinical practice for 
PsA, was performed. We used a modified 
Delphi technique in which questionnaire 
rounds were followed by a well-structured 
meeting of the Steering Committee, to dis-
cuss and validate (by voting) the results. 
Delphi questionnaire preparation
Articles published in indexed English lan-
guage journals on randomized controlled 
clinical trials, meta-analysis, guidelines, 
reviews and observational studies dealing 
specifically with psoriatic arthritis and its 
comorbidities, were selected by the authors. 
The articles were identified by a MEDLINE, 
EMBASE, Cochrane Library, PubMed us-
ing the keywords psoriatic arthritis and/or 
psoriasis, matched with several keywords, 
relevant for every aspect of the diseases, in-
cluding also the term comorbidities.
On the basis of the literature search, we 
identified a preliminary list of 202 poten-
tial items useful for assessment of PsA, 
subdivided in key domains necessary to as-
sess and possibly to distinguish PsA from 
other rheumatic diseases. In particular the 
key domains were: musculoskeletal, der-
matological, metabolic, cardiologic, psy-
chiatric and quality of life related, gastro-
enterological, and ophthalmologic.
The survey
the steering committee planned at least two 
Delphi rounds. The consensus process was 
conducted via email. In the first Delphi 
round the experts judged each of the 202 
items using a score ranging from 1 to 9 
based on its increasing clinical relevance. 
The questions posed to experts was How 
relevant is this procedure/observation/
sign/symptom for assessment of a psoriatic 
arthritis patient? Proposals of additional 
items, not included in the questionnaire, 
were also encouraged. Crucial to the final 
results were: speed of transmission, main-
tenance of respondent anonymity, and po-
tential for rapid feedback.
The agreement was defined when a score 
was reached by at least 80% of the experts. 
The criteria for agreement and disagreement 
between experts were defined as follows:
1) agreement - when 80% of the panel-
lists’ ratings fall into one of the 3-bands 
in a scale from 1 to 9 (1-3; 4-6; 7-9);
2) disagreement - when 90% of the panel-
lists’ ratings fall instead into one of two 
extra-wide bands (1-6 or 4-9).
It means that if, to reach the 90% votes, we 
need to include two large intervals, the dis-
tribution is too skewed and not symmetri-
cal. As such, it represents disagreement.
In the second round, participants were 
asked to rate again only the procedure that 
did not reach the optimal levels of agree-
ment and disagreement. 
The results of the poll were discussed by 
the Steering Committee, which evaluated 
the necessity for removing selected proce-
dures or adding additional ones, according 
to criteria of clinical appropriateness and 
sustainability.
The final list, made of 43 items grouped 
in the previously agreed key domains, was 
discussed in a first 1-day National Expert 
Meeting in October 2014, involving 30 
participants. Further, in this meeting it was 
decided to use the items to prepare an al-
gorithm to assess the patient in daily clini-
cal practice. In light of this, an additional 
round of the Delphi exercise was prepared 
to select through a priority level (high, me-
dium, low) those items considered worthy 
of inclusion in the different steps of the 
flow-chart (laboratory data, history, physi-
cal exam, etc). The main steps of the study 
are reported in Figure 1.
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Calculations were performed using the Of-
fice 2007 software package.
n	 RESULTS
A total of 43 recommended diagnosis 
and assessment procedures, recognized as 
items, were derived by a combination of 
the Delphi survey and two National Expert 
Meetings, and grouped in different areas 
including medical (familial and personal) 
history, physical evaluation, imaging tool, 
second level laboratory tests, disease activ-
ity measurement and extrarticular manifes-
tations (Table I). For each of these, the fre-
quency of high, middle and low priorities 
are also reported.
A first level laboratory tests area was also 
Figure 1 - Main steps of the italian Delphi in psoriatic arthritis (iDea) project.
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Table I - The 43 recommended diagnostic and assessment procedures, recognized as items, derived 
by combination of the Delphi survey and two national expert Meetings, and grouped in different areas 
including medical (familial and personal) history, physical evaluation, imaging tool, second level laboratory 
tests, disease activity measurement and extrarticular manifestations. 
area Item
1st level laboratory tests Cellular blood count (CBC)
1st level laboratory tests Creatinine
1st level laboratory tests alT/gpT
1st level laboratory tests eSr
1st level laboratory tests Crp
1st level laboratory tests Urinalysis
Medical history Diagnosis of psoriasis and/or psoriatic onychopathy
Medical history psoriasis in 1st and 2nd degree relatives
Medical history Site and symptoms characteristics (pain and/or swelling  
and/or stiffness)
Medical history Symptoms duration
Medical history arthritis and/or spondylitis familiarity
Family medical history personal or familiar hystory of inflammatory bowel disease
physical evaluation Site and number of swollen joints
physical evaluation Site and number of tender joints
physical evaluation insertional pain in enthesitis sites
physical evaluation in case of axial disease pattern, clinimetric evaluation of the spine 
(tragus-to-wall distance, lateral bending, Schober’s test, cervical 
spine rotation, inter-malleolar distance)
physical evaluation presence of psoriasis and/or onychopathy
imaging X-ray of the involved joints
imaging US of the involved joints and enthesis
imaging Mri of the sacroiliac joints
2nd level laboratory tests Crp
2nd level laboratory tests Hla-B27 (only if axial and/or enthesis symptoms)
2nd level laboratory tests aCpa + rheumatoid factor
2nd level laboratory tests Uricaemia
involved sites pattern of localization of disease symptoms
Disease activity measurement number of tender joints (TJ 68) and swollen joints (SJ 66)
Disease activity measurement lei (0 - 6)
Disease activity measurement pain VaS (0 - 10)
Disease activity measurement BaSDai
Disease activity measurement BaSFi
Disease activity measurement pga (0 - 10)
Disease activity measurement HaQ
Comorbidities Cardiovascular events, hypertension, diabetes, obesity, dyslipidemia 
ed hyperuricemia
Comorbidities general visit (heart, lung, abdomen, skin and annexes)
Comorbidities Sending the specialist areas of expertise must be selective and based on patient characteristics
ocular comorbidity active uveitis and relapses number
>>> segue
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added by expert committee members as de-
scribed successively.
Anamnestic data 
In the anamnestic phase, for each patient 
suspected of PsA, useful investigations 
were represented by diagnosis of psoriasis 
and/or psoriatic onychopathy in personal 
history (favorable opinion in 100% of 
cases with high priority in 100%) and of 
psoriasis in 1st and 2nd degree relatives (fa-
vorable opinion in 100% of cases with high 
and middle priority respectively, in 92.6% 
and 7.4%). 
Other important anamnestic aspects for 
PsA diagnosis were considered familial 
history for arthritis and spondylitis (fa-
vorable opinion in 96% of cases with 
high, middle and low priority respec-
tively in 37%, 51.9% and 11.1%), site 
and pattern of articular involvement 
(pain, swelling and stiffness) (favorable 
opinion in 89% of cases with high and 
middle priority respectively, in 88.9% 
and 11.1%) and disease duration (favor-
able opinion in 100% of cases with high, 
middle and low priority respectively, in 
59.3%, 33.3 and 7.4%). 
Physical evaluation 
In the context of physical examination, 
favourable opinion was reached in 100% 
of cases for the following items: swollen 
joints count (SJC) (high and middle prior-
ity respectively in 85.2% and 14.8%); ten-
der joints count (TJC) (high, middle and 
low priority respectively in 85.2%, 11.1% 
and 3.7%); tender entheseal sites (high 
and middle priority respectively in 88.9% 
and 11.1%); dactylitis (sites and numbers) 
(high and middle priority respectively 
in 96.3% and 3.7%); clinimetric evalua-
tion of the spine (tragus-to-wall distance, 
lateral bending, Schober’s test, cervical 
spine rotation, inter-malleolar distance) 
(high, middle and low priority respec-
tively in 63%, 33.3% and 3.7%); presence 
of psoriasis and/or onychopathy (high, 
middle and low priority respectively in 
92.6%, 3.7% and 3.7%).
Imaging tools 
Favorable opinion was reached in 100% of 
cases for the following imaging items: X-
ray of the involved joints (high and middle 
priority respectively, in 80% and 20%); US 
of the involved joints and enthesis (high 
and middle priority respectively in 74.1% 
and 25.9%) (high and middle priority re-
spectively in 85.2% and 14.8%); magnetic 
resonance imaging (MRI) of the sacroiliac 
joints in presence of inflammatory back 
pain (high and middle priority respectively 
in 88.9% and 11.1%).
Second level laboratory tests
In the context of laboratory evaluation, fa-
vourable opinion was reached in 100% of 
cases for the following items: HLA-B27 in 
patients with axial and entheseal involve-
ment (high, middle and low priority respec-
tively in 44.4%, 51.9% and 3.7%); C-RP 
(high, and middle priority respectively in 
73.1%, and 26.9%); uricaemia (high, mid-
Physical evaluation Dactylitis (sites and numbers)
gastroenteric comorbidity personal or family history of iBD
Dermatologic comorbidity paSi
psycological comorbidity & Qol presence/absence fybromyalgia
psycological comorbidity & Qol performing of psaiD-12 test is recommended
Dismetabolic comorbidity Metabolic syndrome
Dismetabolic comorbidity obesity
alT/gpT, alanine serum transaminases; eSr, erythrocyte sedimentation rate; Crp, C-reactive protein; US, 
ultrasound; Mri, magnetic resonance imaginf; aCpa, anti-citrullinated protein antibodies; lei, leeds en-
thesitis index; VaS, visual analogic scale pain; BaSDai, bath ankylosing spondylitis disease activity index; 
BaSFi, bath ankylosing spondylitis functional index; pga, patient global assessment; HaQ, health as-
sessment questionnaire; iBD, inflammatory bowel disease; paSi, psoriasis area severity index; psaiD-12, 
psoriatic arthritis impact of disease questionnaire; Qol, quality of life.
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dle and low priority respectively in 29.6%, 
55.6% and 14.8%). 
It was suggested that anti-citrullinated pro-
tein antibodies (ACPA) and rheumatoid 
factor (RF) should be evaluated in case of 
differential diagnosis with rheumatoid ar-
thritis (RA) (high, middle and low priority 
respectively in 37%, 48.1% and 14.8%).
Clinimetric approach 
Favourable opinion was reached in 100% 
of cases for the following clinimetric items: 
68-TJC and 66-SJC (for both, high and 
middle priority respectively in 92.6% and 
7.4% of cases); Bath ankylosing spondyli-
tis disease activity index (BASDAI) (high 
and middle priority respectively in 81.5% 
and 18.5%); Bath ankylosing spondylitis 
functional index (BASFI), health assess-
ment questionnaire (HAQ) and visual ana-
logic scale (VAS)-pain (for all, high and 
middle priority respectively in 63% and 
37%); Leeds enthesitis index (LEI) (0-6) 
(high, middle and low priority respective-
ly in 37%, 51% and 11.1%); PGA (0-10) 
(high, middle and low priority respectively 
in 55.6%, 40.7%, and 3.7% of cases).
Psoriatic arthritis classification
After performing PsA diagnosis, identifi-
cation of clinical subsets, specific disease 
activity scores and clinimetric approach 
were suggested for assessing the disease.
Among these, the most important were con-
sidered to be BASDAI, BASFI, HAQ, VAS 
and PGA in axial pattern; 68-TJC, 66-SJC, 
HAQ, VAS, PGA in peripheral pattern; LEI 
(0-6), HAQ, VAS, PGA in enthesitis; HAQ, 
VAS, and PGA in dactylitis.
Extrarticular manifestations 
After performing PsA diagnosis, identi-
fication of associated extrarticular mani-
festations was considered of relevance as 
result of the study. In particular, the results 
showed the need for investigation on the 
presence of several extrarticular manifesta-
tions and risk factors.
In particular, in the anamnestic phase, the 
results evidenced the need to focus on car-
diovascular events, systolic and/or diastolic 
hypertension, DM, obesity, dyslipidaemia 
and hyperuricemia (favorable opinion in 
100% of cases with high and middle prior-
ity in 74.1% and 25.9%).
The presence of high psoriasis area se-
verity index (PASI), MS, obesity, uveitis 
or recurrence of uveitis, personal and/or 
familial history of IBD, psychological 
comorbidity and low QoL tested by the 
psoriatic arthritis impact of disease ques-
tionnaire, represented important tools for 
addressing the patient towards the special-
ist area of expertise (favorable opinion in 
100% of cases with high, middle and low 
priority respectively in 55.6%, 37%, and 
7.4%).
At the first patient interview, expert com-
mittee members recommended performing 
first level laboratory tests such as cellular 
blood count (CBC), serum creatinine, aspar-
tate and alanine serum transaminases (AST 
and ALT), erythrocyte sedimentation rate 
(ESR), and urinalysis. These were included 
in the first level laboratory tests area. 
In the context of each area, a rank was as-
signed for each item by Expert Committee 
members, in order to create the logical se-
quence for the algorithm.
The final list of recommended diagnosis 
and assessment procedures, by the Delphi 
survey and the two National Expert Meet-
ings, is shown in Table I and as an algo-
rithm in Figure 2.
n	 DISCUSSION
This study shows results obtained by the 
combination of a Delphi survey of a group 
of Italian rheumatologists and two Nation-
al Expert Meetings, created with the aim of 
establishing a clinical procedure and algo-
rithm for the diagnosis and the assessment 
of PsA patients.
In PsA, due to the absence of recent diag-
nostic criteria and of well-defined indices 
assessing the heterogeneity of the condi-
tion, both diagnosis and assessment need 
of be deeply investigated. Reduction of 
PsA severity, improvement of QoL and 
psychosocial components are mainly re-
lated to early diagnosis and appropriate as-
sessment with prompt therapeutic interven-
tion (32-34).
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The final goal in PsA therapy is to inhibit 
structural radiological damage, induce 
clinical remission, and improve patients’ 
QoL, as defined by GRAPPA and the Eu-
ropean League Against Rheumatism in the 
European League Against Rheumatism 
(EULAR) recommendations (19, 35-38).
Hence, we have hypothesised a Delphi 
study for establishing a consensus from 
a large group of rheumatologists with the 
aim of improving PsA early diagnosis and 
assessing the disease and its heterogeneous 
aspects.
Forty-three recommended items reach-
ing high frequency of favourable opinion 
in this study included both diagnostic and 
assessment procedures. Items were then 
grouped in different areas covering medi-
cal (familial and personal) history, physical 
evaluation, imaging, second level laborato-
ry tests, disease activity measurement and 
extrarticular manifestations (ocular, gastro-
intestinal, dermatological, psychological, 
and dismetabolic manifestations). A first 
level laboratory tests area was also added 
by expert committee members.
In particular, the results of the study showed 
that diagnosis of psoriasis and/or psoriatic 
onychopathy in personal history, psoriasis 
in 1st and 2nd degree relatives, familiar his-
tory for arthritis and spondylitis, articular 
site and pattern, and disease duration rep-
resented the most important anamnestic 
items. In the context of physical evalua-
tion, the most important items were rep-
resented by dactylitis (sites and numbers), 
presence of psoriasis and/or onychopathy, 
tender entheseal sites, SJC and TJC, clini-
metric evaluation of the spine (tragus-to-
wall distance, lateral bending, Schober’s 
test, cervical spine rotation, inter-malleolar 
distance). Articular X-rays, US of the in-
volved joints and enthesis and MRIs of the 
sacroiliac joints in presence of inflamma-
tory back pain provided the most important 
imaging findings.
Figure 2 - italian Delphi in psoriatic arthritis (iDea) algorithm reporting the final list of recommended diagnosis and 
assessment procedures, by the Delphi survey and the two national expert Meetings.
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The following key laboratory findings were 
suggested: C-RP, HLA-B27 in patients 
with axial and entheseal involvement, and 
uricaemia. ACPA and RF were considered 
important in the differential diagnosis with 
RA. Further, first level laboratory tests 
such as CBC, serum creatinine, AST and 
ALT, ESR, and urinalysis were recom-
mended by expert committee members, to 
be performed at the first patient interview.
With regard to the clinimetric approach, 
the most important items were represented 
by 68-TJC and 66-SJC, BASDAI, BASFI, 
HAQ, VAS-pain, LEI (0-6), and PGA (0-
10).
In addition, expert committee members 
recommended the calculation of the DAP-
SA score (39). Disease activity index for 
psoriatic arthritis (DAPSA) is a disease-
specific validated and feasible tool for PsA 
assessment. Recently, DAPSA has been 
considered as reference tool for defining 
remission or low disease activity within the 
first recommendation of the latest EULAR 
recommendations on PsA (38).
Anamnestic investigation on the presence 
of cardiovascular events, systolic and/or 
diastolic hypertension, DM, obesity, and 
dyslipidemia were suggested as important 
findings for the assessment of the disease.
Among extrarticular manifestations, the 
presence of high PASI, MS, obesity, uveitis 
or recurrent uveitis, personal and/or famil-
ial history of IBD, and psychological as-
pects needed to be evaluated. 
In order to find accurate and practical di-
agnostic and assessment items in clinical 
practice, we have focused our attention 
on evaluating the different PsA domains. 
Hence, we conceived the IDEA algorithm 
in order to address PsA diagnosis and as-
sessment in the context of daily clinical 
practice. 
In accordance with OMERACT (17) and 
GRAPPA groups (18-22), this study re-
vealed the need to assess PsA with full 
consideration of all major disease domains, 
including peripheral arthritis, axial disease, 
enthesitis, dactylitis, and psoriasis, both in 
anamnestic and clinical evaluation. 
In particular, in this study, the presence of 
arthritis, dactylitis, enthesitis and axial in-
volvement in the context of psoriasis and/
or its familiarity are confirmed as the main 
clinical items useful in addressing the di-
agnosis. Peculiar MRI and US imaging 
findings of involved articular and entheseal 
districts, evaluation of C-RP and HLA-
B27 positivity in case of axial involve-
ment emerged as important elements for 
addressing the diagnosis and assessing the 
disease. RF and ACPA seronegativity rep-
resent useful findings for excluding RA. 
Further, in accordance with GRAPPA rec-
ommendations (18-22), this study confirms 
that rheumatologists should be also aware 
of differing extrarticular conditions, which 
require expert consultation to guarantee 
prompt global assessment.
n	 CONCLUSIONS
In conclusion, the IDEA algorithm could 
represent a useful and practical tool for 
addressing the diagnosis and for assessing 
appropriately the disease. In addition, this 
algorithm might eventually lead to a mul-
tidimensional approach in which rheuma-
tologists have to consider not only articular 
and cutaneous aspects, but also systemic 
aspects. 
However, the elaborated algorithm needs 
to be further investigated in daily prac-
tice, for evidencing and for proving its 
eventual efficacy in detecting and staging 
appropriately PsA and its heterogeneous 
spectrum. 
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